Clinical Trial
Accepted on 21 Apr 2025
A Phase 2a Double-Blind, Placebo-Controlled, Randomized Clinical Trial Evaluating the Efficacy and Safety of NuGel, a Novel Topical GPCR19-Mediated Inflammasome Inhibitor, in Patients with Mild to Moderate Atopic Dermatitis: A Proof-of-Concept Study with Post-Hoc Biomarker Analysis
in Inflammation
- 156 views